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Seizure is the uncoordinated electrical discharge of neurons in the brain. The brain's electrical signaling is maintained by the balance of the excitatory and inhibitory neurotransmitters, glutamate and gamma-Aminobutyric acid (GABA), respectively (Petroff, 2002 ). An imbalance in the activity of either of these neurotransmitters can cause seizure episodes. Seizures are defined behaviorally as involuntary muscle jerks or spasms.
In the absence of a stimulus, MPS IIIA mice do not show visible signs of seizure. However, we hypothesized that in response to a stimulus, MPS IIIA mice can develop seizure and the change in seizure threshold can be scored. This seizure test can be developed into an assay to examine CNS alterations during disease progression or as a benefit of treatment.
Although diseased animals do not exhibit seizures, seizure is a common symptom in MPS IIIA human patients. A study on the natural history of the disease in Spain,
reported that 45% of patients develop recurring generalized seizures at a median age of 8. 
MATERIALS AND METHODS

Animals
All animal procedures were performed in accordance to national standards of the 
Barnes Maze
The were changed after every single animal to eliminate odor biases between animals. Several stationary visual cues were placed in the room as the animal's reference point for locating the escape box, and a stimulus (noise) was used to motivate an escape response. Prior to start of any trial, the animal was habituated to the escape box for 3 minutes. After habituation, the mouse was placed in the middle of the maze under a box. The trial starts upon lifting the box, the stimulus (a steady noise generated by a metronome) turned on and the animal released to find the escape box. During the trials, the animal was given up to 3 minutes on the first trial and 1 minute on subsequent trials. An additional aversive stimulus (clapping) was given if the animal failed to locate the escape box in 1 minute. Once the animal was in the escape box, the noise stimulus was turned off and the animal was allowed to stay in the escape box for another minute. Time latencies were manually recorded at every trial. The maze was sprayed with 70% ethyl alcohol and wiped dry to minimize olfactory cues after every trial. An overhead camera was positioned above the maze for video recordings, this will allow for a variety of data (speed/velocity, time latencies, distance traveled or heat maps) to be analyzed with an automatic video tracking software (EthoVision XT 11).
The BM was used in two different experimental designs. The first experimental protocol was an acute 1-day acquisition phase. The acquisition phase is where the animal initially learns to find the escape box. During the acquisition phase, the animals received 8-10 learning trials until the mice gave a time latency of less than 1 minute, in locating the escape box, on 3 consecutive trials. The animals were tested for memory at 24 hour and 48 hour consisting of 3 trials, post the acquisition trials. The second protocol extended the acquisition phase over 4 days and consisted of only 2 trails per day. The animals were tested for memory on day 5 and 15.
Novel Object Recognition
The NOR test was administered to assess recognition memory deficits in MPS IIIA mice at 4, 12 and 24 weeks. The test was conducted in an opaque shoebox cage arena that measured 18 cm x 28 cm x 4.5 cm high. The objects, as shown on Figure 2 , are plastic that varied in shape and color (width=3.4-4.0 cm; height=4.0 cm) and were placed 13 cm apart to the floor of the cage. The cage did not contain bedding to minimize any distractive elements and the objects were secured with tape to prevent the The objects used in NOR were odorless; similar in height and texture; different in shape and color. Objects were washed and cleaned after every animal to remove possible olfactory cues. analyze the animal's interest towards the novel object.
Animals were placed in an empty cage for 10 minutes during habituation. 2 identical objects are placed in the cage and mice were allowed to explore them. To test recognition memory, one of the objects are replaced for a novel one. Animals explored the objects for 10 minutes at each of the phases. 
PTZ-Induced Seizure Test
The PTZ induced seizures either via an IV continuous infusion or IP kindling was done to assess seizure thresholds in MPS IIIA mice when compared to C57Bl6/J control group at 4, 12 and 24 weeks.
Drug
PTZ (Sigma Aldrich, St. Louis, MO) is kept in -20°C and brought up to room temperature prior to formulation. PTZ was weighed into a glass vial and sterile 0.9% saline was added to achieve designated concentrations. All formulations were prepared fresh on the day of each experiment.
Seizure stages with PTZ induction
PTZ has been shown to elicit distinct individual seizure stages (Da Silva, Pereira e Elisabetsky, 1998; Dhir, 2012). Animals received a single IP administration of PTZ at a convulsive dose of 60 mg/kg and seizure activities were observed to ascertain that PTZ can produce seizures that we are able to score in MPS IIIA.
PTZ is a fast acting drug that was able to elicit a full blown seizure within 5 minutes post IP injection. Seizure activity progresses through three distinct stages ( Figure 5 ). Stage 0 decreased the animal's activity but did not produce seizures. Stage 1 showed involuntary muscle jerks. Stage 2 is often referred to as Straub's tail (Dhir, 2012) , where the tail erects and is perpendicular to the body. Stage 3 is a full blown body muscle contraction, sometimes accompanied with vocalization, lasting from 7 to 30 seconds.
PTZ-induced IV Infusion
Animals were weighed prior to study start. 
PTZ pharmacokinetic (PK) evaluation
For brain and plasma PTZ levels, animals were assigned to study groups as described on Table 1 . Animals received a single IP administration of PTZ and were euthanized at specified time points. Animals were anesthetized using isoflurane and blood sample was collected via cardiac puncture into K3 EDTA anticoagulant tubes which were kept on ice until centrifugation at 10,000 RPM for 5 min at 4°C. Animals were decapitated to remove the brain. The brain was separated into 2 hemispheres, right and left, and placed into two different 2 mL Eppendorf tubes. The plasma was aliquoted into two 1.5 mL Eppendorf tubes. Plasma and brain samples were stored in a -80°C freezer until submission. Samples were sent to Climax Laboratories Inc. (San Jose, CA) for PTZ brain and plasma measurements by mass spectrometry analysis. 
RESULTS
MPS IIIA is marked by neurological consequences, such as cognitive impairment and seizure. In this thesis, we assessed and demonstrate the cognition and seizure performance of MPS IIIA mice in 1) the Barnes Maze and Novel Objection Recognition assays to evaluate learning and memory and 2) by PTZ seizure induction experiments to measure seizure susceptibility.
Behavioral Tests
The Barnes maze does not detect early spatial memory deficits in the MPS IIIA mice
Spatial memory and learning deficits in the MPS IIIA mice have been reported at 20 weeks using the MWM (Fraldi et al., 2007) . Here we use a similar behavioral test, the
Barnes maze. The BM has been shown to be sensitive to changes in spatial learning related to neurodegeneration (Kennard, 2012) . To determine whether we can detect a deficit in spatial learning and memory earlier than the 20 weeks reported with MWM, we tested MPS IIIA animals in the BM.
The data from the 1-day learning and memory method suggests that diseased animals have similar spatial learning and memory abilities as in the normal mice. The 1-day BM learning method was designed to assess acute learning and memory using 9-10 consecutive trials followed by a 24 and 48 hour memory tests. As shown on Figure 6 , there was evidence of normal learning across all the ages tested as measured by performance in each of the training trials (A-C). The quick succession of learning trials in the 1-day protocol may have strongly reinforced learning and memory to be able to see any differences in behavior. To determine whether with less trials and a prolonged learning phase with BM can better assess differences in performance, we extended the training trials over 4 days at 2 trials per day.
To provide a greater memory challenge, the memory test was conducted at day 5 (24 hours) and then delayed until day 15. 
Novel object recognition showed decreased exploratory behaviors
The NOR test, unlike the BM or MWM, relies on the rodent's spontaneous exploratory behavior with no positive or negative reinforcements, such as a reward or punishment. The animals were tested using the NOR assay to determine if the natural tendency of an animal to explore a novel object can be used to detect alterations in recognition memory.
The NOR data are presented on Figure 6 . In the familiarization session (A-C), all the animals showed similar number of exploration pokes between the two identical objects.
The diseased animals seem to exhibit lower number of nose pokes as compared to controls but the difference was not significant. The mean numbers of nose pokes for controls were 
PTZ-induced Seizure Tests
The results from BM did not suggest cognitive decline even at 24 weeks. The results with NOR also did not demonstrate a conclusive difference between normal and MPS IIIA animals. Perhaps stimulation of the CNS might bring about a phenotype that is CNS specific and can be measured prior to 20 weeks. To determine if seizure susceptibility is altered in MPS IIIA mice, we administered PTZ via the IV infusion and IP kindling experimental methods.
There is no significant difference in seizure thresholds with PTZ-induced seizure via the IV infusion
The time latency for the onset of a full blown stage 3 seizure is presented in Figure   9A . Animals were administered with 10 mg/mL of PTZ at a slow constant infusion rate of 50 uL/min and the appearance of seizure stages were observed and recorded and the seizure threshold dose were calculated. There were no significant difference (p=0.58) in the onset of stage 3 seizures between the control and diseased animals. There was also no significant difference in seizure threshold as presented in Figure 9B . Similar threshold doses elicited stage 3 seizures for all animals (4 weeks: 69.7 ± 13.1 mg/kg C57; 66.3 ± 20 mg/kg MPS IIIA, 12 weeks: 53.6 ± 3.9 mg/kg C57; 62.4 ± 22.3 mg/kg MPS IIIA and 24 weeks: 68.9 ± 5.9 mg/kg C57; 62.6 ± 15.6 mg/kg MPS IIIA).
The data on the induction of seizure via an acute IV infusion collectively indicates that there was no detectable difference on seizure onset and threshold between normal and diseased animals via this method. PTZ-induced Seizures via IV Infusion PTZ was administered at 10 mg/mL at a constant rate of 50 uL/min. The onset of the first sign of seizure and a full blown epileptic episode was recorded. Threshold doses at mg/kg was calculated based on animal body weight, PTZ concentration, the IV infusion rate and seizure onset (seconds). (A) Seizure thresholds dose did not show a significant difference at 4, 12 and 24 weeks. The same dose elicit similar seizures in the animals (B) The time latency (s) for the onset of stage 3 seizure was not significant, p=0.58. This data was not normalized to animal body weight.
There was a delay in the onset of PTZ-induced IP kindling
An acute method of inducing seizure with PTZ was not able to show differences in seizure thresholds. We then examined if by using a chronic kindling method, we can see a defect in the adaptive changes in seizure susceptibility in MPS IIIA mice as compared to normal mice. Animals were administered with a subconvulsive dose of PTZ at 40 mg/kg every other day and observed for seizure onset, stages and time to kindle.
The kindling results are presented in Figure 10 . 
Similar PTZ levels at a single dose of 40 mg/kg
To confirm that the PK of PTZ is not altered in MPS IIIA mice and that the kindling effect was not due to changes in PTZ brain penetration, we measured brain and plasma PTZ levels at 5 and 15 minutes following a subconvulsive dose of 40 mg/kg.
As shown in Figure 11 , PTZ brain concentrations for MPS IIIA were comparable to normal controls (wildtype and heterozygous) at both time points. At 5 and 15 minutes, the PK trends the same with that of reported PTZ curves at 55 and 85 mg/kg doses 
DISCUSSION
In this study, we investigated potential early CNS phenotypes in the MPS IIIA mice: spatial learning and memory and seizure threshold. In general, we found that both the Barnes maze and novel object recognition assays do not detect a robust phenotype earlier than 20 weeks. But, with the PTZ seizure assay, CNS stimulation showed a significant delay in kindling response by 12 weeks, with a slight trend as early as 4 weeks.
Based on published results, animal work with the MPS IIIA mouse model has not been able to consistently demonstrate CNS-related defects earlier than 20 weeks of age. The seizure sensitivity data in diseased animals can be exploited to advance the understanding of disease biology. Furthermore, a seizure assay can be developed to screen for viable therapies.
Barnes Maze fails to detect cognitive defects in MPS IIIA mice
The Barnes maze was used to test spatial learning and memory in MPS IIIA mice.
Prior work has shown that BM can measure CNS-related cognitive impairments. Our analysis however, did not show a performance difference between normal and MPS IIIA mice at 4, 12 and 24 weeks of age. Learning abilities appeared normal as both the control and diseased animals consistently learned to locate the escape box with the same amount of trials. Memory also appeared intact as the mouse was able to locate the escape box at 24 hours, 48 hours and even 15 days after having learned the task. This data suggests that there may not be a significant cognitive impairment in MPS IIIA animals before 24 weeks of age in the BM. Performance can also be altered by other stress-induced behaviors that are different between BM and MWM, such as thigmotaxis and passivity. Thigmotaxis is when an animal swims closer to the wall, "wall-hugging", and passivity is the reduction in swimming speed or frequent floating. Both are behaviors exhibited by the animals when using the MWM that occur in response to a stressful environment. These behaviors can affect the results of a MWM experiment. As the animal's anxiety increases, the time latency for escape may also increases. There may be a difference in stress response between normal and MPS IIIA animals that can confound the analysis of the maze results.
The data can be misinterpreted as a decrease in spatial learning and memory specifically, when in fact there was minimal or no defect at all. Thigmotaxis and passivity are not noted in the Barnes maze.
The differences in the mazes likely affect the kind of data being generated. The MWM do not report a phenotype earlier than 20 weeks. It's possible that the stress factor present allowed some distortion of the parameters being measured. This fact about the MWM brings into question the robustness of the maze. The BM being a potentially less stressful version of MWM did not reveal any differences even by 24 weeks. Although the BM has been established for memory assessment, it's possible that it is not sensitive enough to identify phenotypic differences in the MPS IIIA mice. To further determine if there are learning and memory deficits in the diseased mice before 24 weeks when some of the problems in the mazes are addressed, we employed the novel object recognition assay.
Poor recognition and general lack of interest in objects for MPS IIIA mice
The NOR is an attractive test to use as it does not require long animal training and addition, it appears that the MPS IIIA mice had an overall reduced interest in exploring objects. Thus, it is difficult to interpret whether the loss of novel object recognition should be attributed to the inability to remember a familiar object or to the lack of interest for objects in general. This decrease in exploratory behavior, even at the initial presentation of the objects, could have reduced the resolution of the data.
While NOR and MWM or BM are able to track CNS disease progression in MPS IIIA mice with greater sensitivity, they are not direct measurements of CNS activity. An assay that can challenge the CNS directly in order to elicit a specific neurological reaction can perhaps measure an early CNS phenotype in MPS IIIA mice.
A significant effect in PTZ chronic kindling in MPS IIIA mice
Although seizure is prevalent in MPS IIIA patients, it has not been reported in the mouse model. We chose to induce seizure using a convulsive drug for the following reasons. First, drug-induced seizures produce brain related phenotypes, as the compound we used, in this case PTZ, targets neurotransmitter receptors in the CNS. Second, drug levels and subsequent seizure induction can be controlled to accurately measure changes in intensity and threshold of seizure. Lastly, Seizure induced by PTZ is a well-known assay to quantify seizure onset and has been used to determine drug efficacy for AEDs (Orloff, Williams e Pfeiffer, 1949; Mandhane, Aavula e Rajamannar, 2007).
We utilized two seizure assays to test different aspects of seizure threshold, the IV infusion and IP kindling. The IV infusion has been reported to be an accurate technique to record seizure threshold doses in mice (Mandhane, Aavula e Rajamannar, 2007). The IV infusion conceivably can detect neurotransmitter defects that are present in the CNS.
Initially anticipating that there may not be a major difference in neurotransmitter balance or GABA receptor activity in MPS IIIA mice but there may be a difference in how the CNS adapts to PTZ stimulation, a repeated dose of PTZ was administered. The repeated administration of a sub convulsive dose of PTZ elicits an imbalance in neuronal activity over time (Da Silva , Pereira e Elisabetsky, 1998; Dhir, 2012) . This is defined as kindling.
Similar to published reports, we were able to score the stages and timing of seizure development in both the IV infusion and IP kindling methods (Da Silva, Pereira e Elisabetsky, 1998; Dhir, 2012).
PTZ via an IV infusion elicited the same seizure effect in both normal and MPS IIIA animals. The fact that a similar PTZ dose elicited the same seizure excitation in the animals ( Figure 12A and 12B) may mean that there is no defect in GABA receptor or neurotransmitter imbalance in MPS IIIA mice. The infusion data here supports the BM results obtained, where there was no difference between the WT and MPS IIIA at any age.
Surprisingly, our data revealed a delay in seizure kindling when MPS IIIA mice were repeatedly stimulated ( Figure 12D ). This result is interesting because based on human clinical data we hypothesized that MPS IIIA mice would be more sensitive to seizure induction and would have a reduced threshold to PTZ compared to control mice.
Instead, MPS IIIA mice appear to be more resistant to PTZ. When we measure the PTZ levels in the brain, the concentrations were the same in MPS IIIA and normal mice. This demonstrates that the distribution of PTZ is similar between mice and thus, validates the seizure phenotype.
As unexpected as our initial seizure data is, it opens new avenues for opportunities to fully understand the nuerological consequences of lysosomal function impairement to maintaining homeostatis in the brain. In order to expand our understanding of how brain mechanisms adjust in the presence of an insult, glutamate and GABA activity can be measured to determine the stability of these neurotransmitters with chronic PTZ dosing.
This will begin to elucidate the molecular mechanism involved. In addition, rescue of the disease with gene therapy as has been reported (Fraldi et al., 2007; Aronovich e Hackett, 2015) . Future experiments attempting to genetically correct the disease in the CNS of young animals can determine whether seizure is a reliable phenotype to measure for an assay.
PTZ induction produced the earliest CNS specific phenotype recorded. Kindling difference was statistically significant at 12 weeks with a large range for assay development. The subsequent normalization of the seizure threshold will validate PTZ kindling as a method for assessing the benefit of novel drug therapies for MPS IIIA. 
CONCLUSION
This thesis project presents findings on an early CNS behavior phenotype in MPS IIIA mice. We are the first to characterize seizures across three age groups of MPS IIIA animals. In contrast to the data obtained with the learning and memory assays, PTZinduced seizures yielded a significant difference at 12 weeks. The delayed onset of kindling seizure was unexpected but nonetheless, this was an early phenotypic change that appears to have a wider range of difference between control animals to warrant further investigation and assay development. Our results can therefore help establish a working in vivo assay, where seizure is a possible endpoint in the MPS IIIA disease model.
